MIP Discovery, an innovative developer of non-biological affinity reagents designed to accelerate the development and production of cell and gene therapies, has closed a £7m (~$9m USD) Series A financing round led by Mercia Ventures. Existing investor Calculus Capital also participated in the round, along with Angel investors.